文献速递神经肿瘤

神经肿瘤领域立体定向激光间质热疗(LITT)技术扩散模式

Pattern of technology diffusion in the adoption of stereotactic laser interstitial thermal therapy (LITT) in neuro-oncology.
PubMed 文献 · J Neurooncol · 2021-06-13

基于美国国家住院样本数据库(NIS,2012-2018)分析成人原发或转移性脑肿瘤患者接受LITT或开颅手术的特征与结局。LITT使用量相对开颅手术增长约400%,但总量仍不足开颅手术的1%;LITT患者更年轻、女性、非黑人、有私人保险、合并症少于2种,住院时间缩短50%,但手术相关费用与开颅手术相当。

要点

  • LITT使用量相对开颅手术增长约400%,但总量仍不足开颅手术的1%。
  • LITT患者更可能年轻、女性、非黑人、有私人保险、合并症少于2种。
  • LITT住院时间较开颅手术缩短50%,但手术相关费用相当。

核心结论

  • 神经肿瘤适应症中LITT使用量相对开颅手术增长约400%,但总量仍不足开颅手术的1%。
  • LITT患者较开颅手术患者更可能年轻、女性、非黑人、有私人保险、合并症少于2种。
  • LITT住院时间较开颅手术缩短50%,但手术相关费用与开颅手术相当。

研究设计与样本

  • 使用美国国家住院样本数据库(NIS)2012-2018年数据,纳入年龄≥18岁、诊断原发或转移性脑肿瘤并接受LITT或开颅手术的患者。
  • 比较接受LITT与开颅手术患者的特征和结局。

主要发现

  • 研究期间LITT使用量相对开颅手术增长约400%。
  • LITT手术总量仍不足开颅手术的1%。
  • 调整时间趋势后,LITT患者合并症>2种的可能性较低(OR 0.64,95%CI 0.51-0.79),年龄较大的可能性较低(OR 0.92,95%CI 0.86-0.99)。
  • LITT患者女性可能性较高(OR 1.35,95%CI 1.08-1.69),白人较黑人可能性较高(OR 1.94,95%CI 1.12-3.36),私人保险较Medicare或Medicaid可能性较高(OR 1.38,95%CI 1.09-1.74)。
  • LITT住院时间较开颅手术缩短50%(IRR 0.52,95%CI 0.45-0.61),手术相关费用LITT较开颅手术高1397美元(95%CI -5790至8584美元)。

临床怎么用

  • LITT作为神经肿瘤治疗选择,使用量增长迅速但总体占比仍低。
  • LITT可能缩短住院时间,但手术相关费用与开颅手术相当。
  • LITT的应用存在年龄、性别、种族和保险类型等差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Understanding factors that influence technology diffusion is central to clinical translation of novel therapies. We characterized the pattern of adoption for laser interstitial thermal therapy (LITT), also known as stereotactic laser ablation (SLA), in neuro-oncology using the National Inpatient Sample (NIS) database. METHODS: We identified patients age ≥ 18 in the NIS (2012-2018) with a diagnosis of primary or metastatic brain tumor that underwent LITT or craniotomy. We compared characteristics and outcomes for patients that underwent these procedures. RESULTS: LITT utilization increased ~ 400% relative to craniotomy during the study period. Despite this increase, the total number of LITT procedures performed for brain tumor was < 1% of craniotomy. After adjusting for this time trend, LITT patients were less likely to have > 2 comorbidities (OR 0.64, CI95 0.51-0.79) or to be older (OR 0.92, CI95 0.86-0.99) and more likely to be female (OR 1.35, CI95 1.08-1.69), Caucasian compared to Black (OR 1.94, CI95 1.12-3.36), and covered by private insurance compared to Medicare or Medicaid (OR 1.38, CI95 1.09-1.74). LITT hospital stays were 50% shorter than craniotomy (IRR 0.52, CI95 0.45-0.61). However, charges related to the procedures were comparable between LITT and craniotomy ($1397 greater for LITT, CI95 $-5790 to $8584). CONCLUSION: For neuro-oncology indications, LITT utilization increased ~ 400% relative to craniotomy. Relative to craniotomy-treated patients, LITT-treated patients were likelier to be young, female, non-Black race, covered by private insurance, or with < 2 comorbidities. While the total hospital charges were comparable, LITT was associated with a shorter hospitalization relative to craniotomy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Johnson RA, Do TH, Palzer EF, et al. Pattern of technology diffusion in the adoption of stereotactic laser interstitial thermal therapy (LITT) in neuro-oncology. J Neurooncol. 2021. PMID: 34120277. doi:10.1007/s11060-021-03760-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。